Physician profile
Robert B Lehr
NPI 1619901634
$10,754.11
in general payments reported to CMS, 2019-2025
28 companies · $2,754 in 2025
The $2,754 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $377 · 2021: $1,249 · 2022: $1,451 · 2023: $2,150 · 2024: $2,139 · 2025: $2,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,656 · Education: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,655.65 |
| Education | $387.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,467.03 | 2019-2025 | |
| Pfizer INC. | $1,311.47 | 2019-2025 | |
| Lilly USA, LLC | $1,181.70 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $1,180.63 | 2020-2025 | Ilumya, Odomzo, Blu-U |
| Regeneron Healthcare Solutions, INC. | $987.46 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $887.37 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $822.88 | 2019-2025 | |
| Abbvie INC. | $686.67 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $419.11 | 2022-2025 | Sotyktu |
| Ucb, INC. | $389.40 | 2019-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $285.60 | 2019-2023 | |
| Galderma Laboratories, L.P. | $188.81 | 2025 | Nemluvio |
| Incyte Corporation | $154.40 | 2021-2025 | Opzelura |
| Amgen INC. | $145.17 | 2020-2024 | Otezla |
| Leo Pharma INC. | $118.93 | 2020-2025 | Adbry |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $104.02 | 2022-2024 | Xolair, Erivedge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.42 | 2023-2025 | Spevigo |
| Zimvie INC. | $80.30 | 2023 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2022 | |
| Arcutis Biotherapeutics, INC. | $34.84 | 2023-2024 | Zoryve |
| Almirall LLC | $29.38 | 2019 | |
| Dermavant Sciences, INC. | $27.16 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.35 | 2025 | Cabtreo, Jublia, Siliq |
| Dermira, INC. | $17.52 | 2021 | |
| Vyne Pharmaceuticals INC. | $16.63 | 2020 | |
| Botanix Sb INC | $15.23 | 2025 | Sofdra |
| Merck Sharp & Dohme LLC | $13.33 | 2019 | |
| Organon LLC | $9.30 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lehr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.